A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia.

CONTEXT: Non-islet cell tumor hypoglycemia (NICTH) results from the hypersecretion of pro-IGF-II by a large, usually mesenchymal tumor. Detection of pro-IGF-II in serum is a potential tumor marker in these patients. OBJECTIVE: The aim of this study was to validate a rapid and reliable method for de...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser: Miraki-Moud, F, Grossman, AB, Besser, M, Monson, J, Camacho-Hübner, C
Format: Journal article
Sprache:English
Veröffentlicht: 2005
_version_ 1826305932052660224
author Miraki-Moud, F
Grossman, AB
Besser, M
Monson, J
Camacho-Hübner, C
author_facet Miraki-Moud, F
Grossman, AB
Besser, M
Monson, J
Camacho-Hübner, C
author_sort Miraki-Moud, F
collection OXFORD
description CONTEXT: Non-islet cell tumor hypoglycemia (NICTH) results from the hypersecretion of pro-IGF-II by a large, usually mesenchymal tumor. Detection of pro-IGF-II in serum is a potential tumor marker in these patients. OBJECTIVE: The aim of this study was to validate a rapid and reliable method for determining serum pro-IGF-II. PATIENTS: Serum samples from 16 patients with NICTH were studied. MAIN OUTCOME MEASURE: The main outcome measure was serum concentration of pro-IGF-II determined by immunoblot analysis of pro-IGF-II and mature IGF-II after 16.5% tricine-SDS-PAGE, which was compared with pro-IGF-II measured by standard RIA after size-exclusion acid chromatography. RESULTS: The analyses of patients' sera by size-exclusion acid chromatography showed that 68 +/- 19% of IGF-II were present in the pro-IGF-II form, whereas only 18 +/- 4% corresponded to pro-IGF-II in controls. Scanning densitometry of immunoblots showed 67 +/- 16% in the bands corresponding to pro-IGF-II in patients' sera, compared with 27 +/- 9% in controls. The detection sensitivity of tricine-SDS-PAGE method was the same as for size-exclusion chromatography, but the tricine-SDS-PAGE method is quicker and requires smaller amounts of serum. CONCLUSION: Tricine-SDS-PAGE followed by IGF-II immunoblot analysis provides a rapid, reproducible, and sensitive method for the separation of serum pro-IGF-II from mature IGF-II and is a useful laboratory evaluation of patients with a clinical diagnosis of NICTH.
first_indexed 2024-03-07T06:40:18Z
format Journal article
id oxford-uuid:f90dd682-4445-48db-b1db-6f3bd5edf153
institution University of Oxford
language English
last_indexed 2024-03-07T06:40:18Z
publishDate 2005
record_format dspace
spelling oxford-uuid:f90dd682-4445-48db-b1db-6f3bd5edf1532022-03-27T12:55:00ZA rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f90dd682-4445-48db-b1db-6f3bd5edf153EnglishSymplectic Elements at Oxford2005Miraki-Moud, FGrossman, ABBesser, MMonson, JCamacho-Hübner, C CONTEXT: Non-islet cell tumor hypoglycemia (NICTH) results from the hypersecretion of pro-IGF-II by a large, usually mesenchymal tumor. Detection of pro-IGF-II in serum is a potential tumor marker in these patients. OBJECTIVE: The aim of this study was to validate a rapid and reliable method for determining serum pro-IGF-II. PATIENTS: Serum samples from 16 patients with NICTH were studied. MAIN OUTCOME MEASURE: The main outcome measure was serum concentration of pro-IGF-II determined by immunoblot analysis of pro-IGF-II and mature IGF-II after 16.5% tricine-SDS-PAGE, which was compared with pro-IGF-II measured by standard RIA after size-exclusion acid chromatography. RESULTS: The analyses of patients' sera by size-exclusion acid chromatography showed that 68 +/- 19% of IGF-II were present in the pro-IGF-II form, whereas only 18 +/- 4% corresponded to pro-IGF-II in controls. Scanning densitometry of immunoblots showed 67 +/- 16% in the bands corresponding to pro-IGF-II in patients' sera, compared with 27 +/- 9% in controls. The detection sensitivity of tricine-SDS-PAGE method was the same as for size-exclusion chromatography, but the tricine-SDS-PAGE method is quicker and requires smaller amounts of serum. CONCLUSION: Tricine-SDS-PAGE followed by IGF-II immunoblot analysis provides a rapid, reproducible, and sensitive method for the separation of serum pro-IGF-II from mature IGF-II and is a useful laboratory evaluation of patients with a clinical diagnosis of NICTH.
spellingShingle Miraki-Moud, F
Grossman, AB
Besser, M
Monson, J
Camacho-Hübner, C
A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia.
title A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia.
title_full A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia.
title_fullStr A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia.
title_full_unstemmed A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia.
title_short A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia.
title_sort rapid method for analyzing serum pro insulin like growth factor ii in patients with non islet cell tumor hypoglycemia
work_keys_str_mv AT mirakimoudf arapidmethodforanalyzingserumproinsulinlikegrowthfactoriiinpatientswithnonisletcelltumorhypoglycemia
AT grossmanab arapidmethodforanalyzingserumproinsulinlikegrowthfactoriiinpatientswithnonisletcelltumorhypoglycemia
AT besserm arapidmethodforanalyzingserumproinsulinlikegrowthfactoriiinpatientswithnonisletcelltumorhypoglycemia
AT monsonj arapidmethodforanalyzingserumproinsulinlikegrowthfactoriiinpatientswithnonisletcelltumorhypoglycemia
AT camachohubnerc arapidmethodforanalyzingserumproinsulinlikegrowthfactoriiinpatientswithnonisletcelltumorhypoglycemia
AT mirakimoudf rapidmethodforanalyzingserumproinsulinlikegrowthfactoriiinpatientswithnonisletcelltumorhypoglycemia
AT grossmanab rapidmethodforanalyzingserumproinsulinlikegrowthfactoriiinpatientswithnonisletcelltumorhypoglycemia
AT besserm rapidmethodforanalyzingserumproinsulinlikegrowthfactoriiinpatientswithnonisletcelltumorhypoglycemia
AT monsonj rapidmethodforanalyzingserumproinsulinlikegrowthfactoriiinpatientswithnonisletcelltumorhypoglycemia
AT camachohubnerc rapidmethodforanalyzingserumproinsulinlikegrowthfactoriiinpatientswithnonisletcelltumorhypoglycemia